Niesen Willem, Hank Thomas, Büchler Markus, Strobel Oliver
Department of General, Visceral and Transplantation Surgery Heidelberg University Hospital Heidelberg Germany.
Ann Gastroenterol Surg. 2019 Jul 1;3(5):464-475. doi: 10.1002/ags3.12273. eCollection 2019 Sep.
Pancreatic cancer remains a therapeutic challenge. Surgical resection in combination with systemic chemotherapy is the only option promising long-term survival and potential cure. However, only about 20% of patients are diagnosed with tumors that are still in a resectable stage. Even after potentially curative resection and modern regimens for adjuvant chemotherapy, the majority of patients develop local and systemic recurrence resulting in median overall survival times of 28-54 months. The predominance of systemic recurrence and its impact on survival may lead to the assumption that surgical radicality and local control play only minor roles in the treatment of pancreatic cancer. This review provides an overview of the recent literature on surgical radicality and survival outcome in pancreatic cancer. The current evidence on the extent of lymphadenectomy, the prognostic impact of the extent of lymph node involvement, and the impact of the resection margin status on postresection survival are reviewed. Data from recent studies performed in the context of modern surgery and adjuvant therapy provide good evidence of a considerable impact of local radicality on survival after pancreatic cancer surgery. Surgical techniques that have been developed to refine oncological resections and to increase local control as well as resectability are highlighted. These techniques include artery-first approaches, level-3 dissection with removal of the periarterial nerve plexus, the triangle operation, and extended resections. Local radicality and quality of surgical resection remain among the most important parameters that determine the chances for survival in patients with non-metastatic pancreatic cancer.
胰腺癌仍然是一个治疗难题。手术切除联合全身化疗是唯一有望实现长期生存和潜在治愈的选择。然而,只有约20%的患者被诊断出肿瘤仍处于可切除阶段。即使经过潜在的根治性切除和现代辅助化疗方案,大多数患者仍会出现局部和全身复发,导致中位总生存时间为28 - 54个月。全身复发的主导地位及其对生存的影响可能导致一种假设,即手术根治性和局部控制在胰腺癌治疗中仅起次要作用。本综述概述了近期关于胰腺癌手术根治性和生存结果的文献。回顾了关于淋巴结清扫范围、淋巴结受累程度的预后影响以及切缘状态对切除后生存影响的现有证据。在现代手术和辅助治疗背景下进行的近期研究数据充分证明了局部根治性对胰腺癌手术后生存有相当大的影响。重点介绍了为优化肿瘤切除、提高局部控制以及可切除性而开发的手术技术。这些技术包括动脉优先入路、切除动脉周围神经丛的3级清扫、三角手术和扩大切除术。局部根治性和手术切除质量仍然是决定非转移性胰腺癌患者生存机会的最重要参数之一。